Search
Georgia Paid Clinical Trials
A listing of 1949 clinical trials in Georgia actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1825 - 1836 of 1949
Georgia is currently home to 1949 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Atlanta, Augusta, Decatur and Savannah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
Buy Retatrutide Online Through Celia
Recruiting
Retatrutide (formerly M25) is an investigational peptide being studied for its potential in supporting weight management and metabolic health. It acts on GLP-1, GIP, and glucagon receptors to influence appetite, energy regulation, and fat metabolism.
Conditions:
Healthy
Featured Offer
Lose 20% of Body Weight With GLP-1's
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to tirzepatide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Birth Control Clinical Research Study
Recruiting
Living with obesity and looking for a birth control option that is right for you? Clinical trials are now enrolling women with a body mass index (BMI) of 30 or more in the area to help study a potential new progestin-only contraceptive patch. Participating in research studies can help advance birth control options. Don’t let financial stress hold you back. All study-related assessments, care, and study patch are available at no cost. You may also be reimbursed for study-related travel.
Conditions:
Obesity
Overweight
Overweight and Obesity
Featured Trial
Depression Clinical Trial
Recruiting
Join us in researching a potential investigational treatment for Depression. Reimbursement for study-related expenses may be available to you.
Qualifying participants:
•Are between 18-65
•Have been experiencing a major depressive episode for at least a month
Qualifying participants:
•Are between 18-65
•Have been experiencing a major depressive episode for at least a month
Conditions:
Depression
Major Depressive Disorder
Depressive Disorder
Depressive Symptoms
Depressive Disorder
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Recruiting
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.
The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia.
In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19.
REMAP-COVID is a sub-platform of REMAP-CAP th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2024
Locations: Augusta University, Augusta, Georgia
Conditions: Community-acquired Pneumonia, Influenza, COVID-19
Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis
Recruiting
Study participants with non-cystic fibrosis bronchiectasis will be given Trikafta for four weeks. The researchers will monitor clinical endpoints, quality of life, and weight. Additionally, cutaneous punch biopsy material material or blood samples from participants who agree to do this optional test will be collected to test cellular response to Trikafta.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2024
Locations: The Emory Clinic, Atlanta, Georgia
Conditions: Non-cystic Fibrosis Bronchiectasis
Implementing Models for Mechanical Circulatory Support Presurgical Assessment in Congenital Heart Disease Treatment
Recruiting
The purpose of this research study is to look at the advantages of using a 3D printed heart model for surgical planning in children who have been diagnosed with Congenital Heart Disease (CHD) and clinical heart failure and will undergo a ventricular assist device (VAD) placement. The investigators want to study the correlation of having a 3D printed model with improvement in patient outcomes and compare those with patients who have had a VAD placement without a 3D model.
Gender:
ALL
Ages:
All
Trial Updated:
07/03/2024
Locations: Children's Healthcare of Atlanta, Atlanta, Georgia
Conditions: Congenital Heart Disease
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
Recruiting
This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
Gender:
ALL
Ages:
All
Trial Updated:
07/02/2024
Locations: Emory University School of Medicine, Atlanta, Georgia
Conditions: Neoplasms
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Phoebe Putney Memorial Hospital, Albany, Georgia
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry (Dexcom Global Registry)
Recruiting
"To evaluate the use of the Dexcom CGM System when used according to approved commercial labeling during standard clinical use and its impact on intended users in a real-world setting"
Gender:
ALL
Ages:
2 years and above
Trial Updated:
06/28/2024
Locations: Institute of Endocrinology Diabetes, Health & Hormones, Stockbridge, Georgia
Conditions: Diabetes
Virtual Reality During Exercise Testing
Recruiting
The goal of this clinical trial is to explore the effects of virtual reality use on maximal aerobic exercise test performance (aerobic capacity) in healthy adults. The main questions it aims to answer are:
* Does using a virtual reality program during a maximal aerobic exercise test lead to differences in VO2peak (maximal aerobic capacity)? and,
* Does using a virtual reality program during a maximal aerobic exercise test lead to differences in work rate at the ventilatory threshold?
Participa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Augusta University, Augusta, Georgia
Conditions: Virtual Reality
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
Recruiting
The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation therapy in patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy.
Tifcemalimab is a monoclonal antibody against B and T lymphocyte attenuator (BTLA). Toripalimab is a monoclonal antibody against programmed death... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital, Marietta, Georgia
Conditions: Limited-stage Small Cell Lung Cancer (LS-SCLC)
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: GSK Investigational Site, Atlanta, Georgia
Conditions: Neoplasms
Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
Recruiting
Assess response to pembrolizumab in both primary tumor, normal breast stroma, circulating lymphocytes and serum exosomes in treatment naive triple negative breast cancer (TNBC) patients.
Assess for change in tumor-infiltrating lymphocytes (TILS) both stromal (sTILS) and intraepithelial (iTILS) in newly diagnosed early stage TNBC patients treated with two doses of MK-3475 prior to lumpectomy.
Gender:
FEMALE
Ages:
Between 21 years and 80 years
Trial Updated:
06/17/2024
Locations: Emory University, Atlanta, Georgia
Conditions: Triple Negative Breast Cancer
Biphasic Effects of Acute Alcohol Intoxication on Bystander Intervention
Recruiting
The goal of this experimental study is to examine the effect of alcohol, gender, and bystander attitudes on bystander barriers and sexual violence intervention among young adult men and women (age 21-20). The main questions it aims to answer are:
* Does alcohol intoxication and gender influence bystander barriers and sexual violence intervention?
* Does alcohol intoxication have a greater impact on bystander barriers and sexual violence intervention among men, compared to women?
* Does alcohol... Read More
Gender:
ALL
Ages:
Between 21 years and 30 years
Trial Updated:
06/10/2024
Locations: Georgia State University, Atlanta, Georgia
Conditions: Alcohol Intoxication
Natural Progesterone for the Treatment of Recurrent Glioblastoma
Recruiting
This early phase I trial identifies the best dose, possible benefits and/or side effects of natural progesterone in treating patients with glioblastoma that has come back (recurrent). Progesterone is a type of hormone made by the body that plays a role in the menstrual cycle and pregnancy. Progesterone may help control tumor growth and spread in patients with glioblastoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/09/2024
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: Gliosarcoma, Recurrent Glioblastoma
